Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3Recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 10Lymphoma 9Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell 4Lymphoma, Non-Hodgkin 3Waldenstrom Macroglobulinemia 2Recurrence 2Lymphoma, T-Cell, Peripheral 2Hodgkin Disease 2Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Hematopoietic and Lymphoid System Neoplasm 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumor 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × Bendamustine Hydrochloride × Clear all
NCT06522737 2026-04-06

TERZO

SecuraBio

Phase 3 Recruiting
124 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡